AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 33586842
Drug: Surgery and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgery and adjuvant radiation therapy
Trial: 32103439
Drug: Intraventricularly delivered,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraventricularly delivered, sustained-release nimodipine (EG-1962)
Trial: 32103439
Drug: Standard of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of care oral nimodipine (NEWTON 2)
Trial: 32680475
Drug: Behavioural group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Behavioural group counselling program for smoking cessation, optional nicotine replacement therapy, environmental smoking reduction measures
Trial: 33513064
Drug: Remote Hypnotic
RxNorm normalized name: Synotic
DrugBank: Fluocinolone acetonide (DB00591)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Remote Hypnotic Induction Profile (rHIP)
Trial: 32681659
Drug: Non-surgical periodontal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-surgical periodontal treatment
Trial: 36296930
Drug: Group cognitive
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group cognitive behavioral therapy (CBT)
Trial: 33442915
Drug: VR intervention
RxNorm normalized name: Prostin VR
DrugBank: Alprostadil (DB00770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: VR intervention (8 h within 2 weeks) plus 8-h occupational therapy (OT)
Trial: 34137527
Drug: Articaine 4%
RxNorm normalized name: ARTICAINE 4%/EPI 1:200000 INJ CART 1.7ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Articaine 4% IANB with Buccal Infiltration
Trial: 34137527
Drug: Lidocaine 2%
RxNorm normalized name: LIDOCAINE 2% GEL,TOP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine 2% IANB with Buccal Infiltration
Trial: 34155568
Drug: Brivaracetam 50
RxNorm normalized name: brivaracetam 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brivaracetam 50 mg/day
Trial: 32728734
Drug: HERO intervention
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: HERO intervention (8-session cognitive-behavioral therapy)
Trial: 34501459
Drug: Electrochemotherapy (ECT)
RxNorm normalized name: ECT-001 expanded cord blood
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electrochemotherapy (ECT) followed by conventional systemic treatment (FOLFOXIRI)
Trial: 34501459
Drug: Conventional chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional chemotherapy (FOLFOXIRI)
Trial: 615704919
Drug: C1INH (20U/kg/dose)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: C1INH (20U/kg/dose) intra-operatively, then 2x weekly for 7 doses
Trial: 34398236
Drug: Romidepsin (RMD)
RxNorm normalized name: Romidepsin
DrugBank: Romidepsin (DB06176)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Romidepsin (RMD) 5 mg/m2 in multidose cohort 4
Trial: 32459776
Drug: Collagenase clostridium
RxNorm normalized name: Collagenase Clostridium Histolyticum
DrugBank: Collagenase clostridium histolyticum (DB00048)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Collagenase clostridium histolyticum injections
Trial: 36858265
Drug: Antidepressant treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antidepressant treatment for 8 weeks
Trial: 32317748
Drug: 320 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 320 mg/day anthocyanin
Trial: 32317748
Drug: Anthocyanin supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anthocyanin supplementation (0-320 mg/day)
Trial: 32317748
Drug: Anthocyanin supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anthocyanin supplementation (80-320 mg/day)
Trial: 32413002
Drug: Contrast-rebalanced binocular
RxNorm normalized name: Contrased
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Contrast-rebalanced binocular game treatment (1 hour a day, 5 days a week)
Trial: 32413002
Drug: Patching treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patching treatment (2 hours a day, 7 days a week)
Trial: 35600486
Drug: Standard statin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard statin therapy
Trial: 32832978
Drug: Fremanezumab (quarterly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fremanezumab (quarterly or monthly dosing)
Trial: 33893671
Drug: Zinc (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zinc (30 mg)
Trial: 34591428
Drug: Regional radiation
RxNorm normalized name: allantoin
DrugBank: Allantoin (DB11100)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Regional radiation therapy 50‐55 Gy and intermediate dose of α2b‐interferon (RT + IFN)
Trial: 34591428
Drug: Intermediate dose
RxNorm normalized name: Prevotella intermedia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermediate dose of α2b‐interferon alone (IFN)
Trial: 34331551
Drug: Indobufen 100
RxNorm normalized name: indobufen
DrugBank: Indobufen (DB12545)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indobufen 100 mg twice daily
Trial: 33481052
Drug: SPP-24 levels
RxNorm normalized name: CAPSICUM SPP.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SPP-24 levels measured in serum using ELISA; mean SPP-24 was 167.7 ± 101.1 ng/mL (range 33.4–633.6 ng/mL)
Trial: 32613644
Drug: Online Acceptance
RxNorm normalized name: FILTER,SUCTION,INLINE #FHBF200S
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Online Acceptance and Commitment Therapy (ACT)
Trial: 34269493
Drug: Online Compassion-Focused
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Online Compassion-Focused Therapy (CFT)
Trial: 34728250
Drug: TAU augmented
RxNorm normalized name: Interferon tau
DrugBank: Interferon tau (DB16972)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAU augmented with the 5-min FoodT app daily for 4 weeks (n = 40)
Trial: 34728250
Drug: Treatment as
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment as usual (TAU; n = 40)
Trial: 33491367
Drug: Conical Standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conical Standard (CS) implants
Trial: 33491367
Drug: Internal Hex
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internal Hex (IH) implants
Trial: 33491367
Drug: CS implants
RxNorm normalized name: MyoGesic-CS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CS implants
Trial: 33491367
Drug: CS and
RxNorm normalized name: HYPNOTICS AND SEDATIVES
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CS and IH implants
Trial: 34515098
Drug: Thulium laser
RxNorm normalized name: thulium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thulium laser (L)
Trial: 34515098
Drug: Combined L-PDT
RxNorm normalized name: L-377202
DrugBank: L-377202 (DB19022)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined L-PDT
Trial: 32796401
Drug: S. boulardii
RxNorm normalized name: Lactobac. plantarum/S. boulardii/Pediococcus acidilactici 8 billion cell ORAL CAPSULE,DELAYED RELEASE (ENTERIC COATED)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S. boulardii CNCM I‐3799 (5 billion CFU twice daily for 5 days)
Trial: 32956178
Drug: Azathioprine (AZA)
RxNorm normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Azathioprine (AZA) monotherapy
Trial: 35533340
Drug: Burosumab (0.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Burosumab (0.8 mg/kg every 2 weeks)
Trial: 34658725
Drug: Target-controlled infusion
RxNorm normalized name: Diphtheria toxin-il-3 fusion protein targeting IL-3 receptor
DrugBank: Tagraxofusp (DB14731)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Target-controlled infusion (TCI) of propofol
Trial: 32851876
Drug: BUP-NX (sublingual
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BUP-NX (sublingual buprenorphine-naloxone)
Trial: 32851876
Drug: XR-NTX (extended-release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: XR-NTX (extended-release injection naltrexone)
Trial: 34619894
Drug: Immediate rehabilitation
RxNorm normalized name: GLUTATHIONE 12.5 g in 100 mL ORAL LIQUID [K2LTS Brain Rehabilitation]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate rehabilitation by using implant-supported full-arch prostheses (TG)
Trial: 34619894
Drug: Immediate rehabilitation
RxNorm normalized name: GLUTATHIONE 12.5 g in 100 mL ORAL LIQUID [K2LTS Brain Rehabilitation]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate rehabilitation of implant-supported full-arch prostheses (CG)
Trial: 33042579
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (not specified, but implied as no treatment)
Trial: 34113318
Drug: rhGH treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rhGH treatment
Trial: 34146512
Drug: Pioglitazone (0.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pioglitazone (0.8 mg/day sustained release)
Trial: 35671649
Drug: Low-dose methotrexate
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose methotrexate (LD-MTX)
Trial: 34606758
Drug: Tablet administration
RxNorm normalized name: tablet administration aid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet administration of FAMCAT
Trial: 34606758
Drug: Interview administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Interview administration of FAMCAT
Trial: 34988564
Drug: Riceberry rice
RxNorm normalized name: Rice
DrugBank: Rice (DB10563)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Riceberry rice beverage (RRB) with HCMF meal (2 g of riceberry rice extract powder/400 ml)
Trial: 33788326
Drug: Complete harm
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Complete harm reduction program (HRP) participation (≥ 60 mg/day methadone and 100% needle and syringe program coverage)
Trial: 33788326
Drug: No HRP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No HRP and partial HRP participation (< 60 mg/day methadone and/or < 100% NSP coverage)
Trial: 32381925
Drug: L-carnitine oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-carnitine oral supplements (group C)
Trial: 32381925
Drug: No L-carnitine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No L-carnitine oral supplements (group N)
Trial: 36384737
Drug: Prednisolone 40
RxNorm normalized name: prednisolone 40 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisolone 40 mg once daily for 10 days
Trial: 36409058
Drug: Sodium chloride
RxNorm normalized name: Sodium Chloride
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium chloride (1 g/d) as an add-on to lithium carbonate
Trial: 33301740
Drug: Short-course radiotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Short-course radiotherapy (5 × 5 Gy over a maximum of 8 days) followed by six cycles of CAPOX chemotherapy or nine cycles of FOLFOX4, followed by total mesorectal excision.
Trial: 33301740
Drug: Standard of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of care: 28 daily fractions of 1.8 Gy up to 50.4 Gy or 25 fractions of 2.0 Gy up to 50.0 Gy with concomitant capecitabine 825 mg/m2, followed by total mesorectal excision and optional adjuvant chemotherapy.
Trial: 34254189
Drug: Insoluble oat
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insoluble oat hulls fibre supplement
Trial: 32532035
Drug: n-3 PUFAs
RxNorm normalized name: 22:6(n-3)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: n-3 PUFAs enriched hen eggs (1053 mg n-3 PUFAs/day)
Trial: 32532035
Drug: Regular hen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular hen eggs (249 mg n-3 PUFAs/day)
Trial: 36069928
Drug: Current diabetes
RxNorm normalized name: Diabetic Tussin EX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Current diabetes care (insulin pump or pen therapy)
Trial: 33963722
Drug: 0.2 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2 μg · kg‐1·h‐1 DEX
Trial: 33963722
Drug: 0.5 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 μg · kg‐1·h‐1 DEX
Trial: 33963722
Drug: 0.8 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.8 μg · kg‐1·h‐1 DEX
Trial: 33025006
Drug: Warm rice
RxNorm normalized name: Rice
DrugBank: Rice (DB10563)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warm rice (14 mg · kg‐1 · d‐1)
Trial: 33025006
Drug: Cold rice
RxNorm normalized name: Rice
DrugBank: Rice (DB10563)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cold rice (14 mg · kg‐1 · d‐1)
Trial: 32758058
Drug: Leucine (1.11
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leucine (1.11 g) + Resveratrol (50 mg)
Trial: 33303111
Drug: Medical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical therapy (in thrombophilia subgroup)
Trial: 35587070
Drug: N-acetylcysteine and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N-acetylcysteine and propolis (NACp) 600 mg
Trial: 35587070
Drug: N-acetylcysteine and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N-acetylcysteine and propolis (NACp) 1200 mg
Trial: 33848070
Drug: Parasacral TENS
RxNorm normalized name: TEN
DrugBank: Pentaerythritol tetranitrate (DB06154)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parasacral TENS administered twice weekly
Trial: 33848070
Drug: Parasacral TENS
RxNorm normalized name: TEN
DrugBank: Pentaerythritol tetranitrate (DB06154)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parasacral TENS administered three times weekly
Trial: 33019888
Drug: Usual care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual care (direct usual care aphasia therapy)
Trial: 33019888
Drug: High intensity
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High intensity group (usual care-plus or prescribed direct aphasia therapy)
Trial: 33771104
Drug: Baroreflex activation
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baroreflex activation therapy plus guideline directed therapy (BAT + GDT)
Trial: 33771104
Drug: Guideline directed
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guideline directed therapy (GDT) alone
Trial: 32975045
Drug: Proton pump
RxNorm normalized name: Proton pump inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Proton pump inhibitor (PPI) treatment
Trial: 35370914
Drug: Optimized acupuncture
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Optimized acupuncture and moxibustion treatment (OAMT), given five times per week for 4 weeks.
Trial: 36329513
Drug: Treamid 50
RxNorm normalized name: Treamid
DrugBank: Treamid (DB16365)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treamid 50 mg once a day for 4 weeks
Trial: 32927285
Drug: Apomorphine sublingual
RxNorm normalized name: apomorphine Sublingual Film
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apomorphine sublingual film (APL) titration (10–35 mg)
Trial: 35068168
Drug: Apomorphine sublingual
RxNorm normalized name: apomorphine Sublingual Film
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apomorphine sublingual film (APL)
Trial: 37578800
Drug: Immediate-release carbidopa-levodopa
RxNorm normalized name: carbidopa / levodopa
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate-release carbidopa-levodopa
Trial: 36279409
Drug: Norepinephrine at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Norepinephrine at a starting rate of 0.05 μg·kg‐1·min‐1 (n = 62)
Trial: 36279409
Drug: Phenylephrine at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phenylephrine at a starting rate of 0.5 μg·kg‐1·min‐1 (n = 62)
Trial: 33646860
Drug: Ketone monoester
RxNorm normalized name: Ketonal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketone monoester (KE) supplement (600 mg/kg body mass)
Trial: 33128085
Drug: Immunohistochemical panel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunohistochemical panel (eight antibodies)
Trial: 38868491
Drug: Trauma-Focused Cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trauma-Focused Cognitive Behavioral Therapy (TF-CBT)
Trial: 32920022
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg of enteric-coated aspirin daily
Trial: 33907782
Drug: Multi-dimensional oral
RxNorm normalized name: Finafta Multi Oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multi-dimensional oral cleaning intervention model
Trial: 35590291
Drug: Routine oral
RxNorm normalized name: Peace Out Acne Hero Routine KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine oral health education (Control)
Trial: 33388951
Drug: Glasdegib (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glasdegib (100 mg, oral, fasted conditions)
Trial: 34183579
Drug: Probiotic (Lactobacillus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic (Lactobacillus rhamnosus GG and a combination probiotic: L. rhamnosus and L. helveticus)
Trial: 33765581
Drug: EAE food
RxNorm normalized name: ALLERGENIC EXTRACT, FOOD, WHEAT
DrugBank: Wheat (DB10579)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EAE food supplement (500 mg daily for 6 months)
Trial: 34529781
Drug: Protocol-driven intensified
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protocol-driven intensified diuretic therapies (n = 43)
Trial: 34529781
Drug: Diuretic-induced natriuresis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diuretic-induced natriuresis
Trial: 34529781
Drug: Pre-diuretic urine
RxNorm normalized name: Urin DS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre-diuretic urine sodium to creatinine ratio
Trial: 35113639
Drug: Emotion-Focused Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Emotion-Focused Therapy (EFT)
Trial: 33971933
Drug: Add‐Aspirin trial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Add‐Aspirin trial with EHR data from NCRAS
Trial: 33971933
Drug: PATCH trial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PATCH trial with EHR data from NICOR
Trial: 33971933
Drug: PATCH trial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PATCH trial with EHR data from NHS Digital
Trial: 39215959
Drug: Clopidogrel monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel monotherapy
Trial: 35365511
Drug: Surgical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical treatment (open reduction and internal fixation)
Trial: 35365511
Drug: Non-operative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-operative treatment (closed reduction followed by cast treatment)
Trial: 33236211
Drug: Decongestive lymphatic
RxNorm normalized name: Qlearquil Nasal Decongestant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Decongestive lymphatic treatment (DLT) consisting of an intensive treatment phase of 3 weeks, followed by a maintenance treatment phase of 6 months.
Trial: 34105695
Drug: Botulinum toxin
RxNorm normalized name: Botulinum toxin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Botulinum toxin type A (BoNT‐A) injections
Trial: 34422049
Drug: Apatinib combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apatinib combined with chemotherapy
Trial: 34058423
Drug: Prophylactic negative-pressure
RxNorm normalized name: polylactic acid-polyglycolic acid copolymer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic negative-pressure wound therapy device
Trial: 35312891
Drug: Tablet-based patient
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet-based patient education tool
Trial: 32338345
Drug: Single-dose apalutamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-dose apalutamide 240 mg
Trial: 35317414
Drug: SQ‐LNS (130
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SQ‐LNS (130 µg selenium/20 g)
Trial: 35317414
Drug: MMN (130
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MMN (130 µg selenium per capsule)
Trial: 32771032
Drug: Hydroxychloroquine Phosphate/Sulfate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydroxychloroquine Phosphate/Sulfate (200 mg orally 8 hourly thrice a day for 5 days)
Trial: 35799756
Drug: Oseltamivir (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oseltamivir (75 mg orally twice a day for 5 days)
Trial: 35799756
Drug: Azithromycin (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin (500 mg orally daily on day 1, followed by 250 mg orally twice a day on days 2‐5)
Trial: 32771032
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Hydroxychloroquine and Oseltamivir
Trial: 32771032
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Hydroxychloroquine and Azithromycin
Trial: 32771032
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Oseltamivir and Azithromycin
Trial: 32771032
Drug: Triple drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple drug regimen (Hydroxychloroquine, Oseltamivir, and Azithromycin)
Trial: 34528576
Drug: Rucaparib (maintenance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rucaparib (maintenance therapy)
Trial: 33372679
Drug: 200 mg/d
RxNorm normalized name: alpelisib 200 mg/day (200 mg x 1) ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg/d resveratrol
Trial: 33423824
Drug: Diazepam (DZP),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diazepam (DZP), doses 5–20 mg IV
Trial: 33423824
Drug: Dexmedetomidine (DEX),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine (DEX), infusion 2–7 mcg/kg/min